Biomea Fusion, Inc. (BMEA) 10-Year Financial Performance & Capital Metrics

BMEA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutBiomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.Show more

Revenue $0
EBITDA -$142M -14.2%
Net Income -$138M -18.1%
EPS (Diluted) -3.83 -11.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -125.38% -48.5%
ROIC -4566.89% +61.6%
Debt/Equity 0.17 +179.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM33.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM40.4%

ROCE

10Y Avg-63.92%

5Y Avg-63.92%

3Y Avg-89.23%

Latest-122.44%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	132K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	-132K	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	1%	-	-	-
Operating Expenses+	1.2M	5.2M	41.67M	83.63M	126.14M	144.07M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	103K	1.52M	13.67M	20.92M	23.59M	25.98M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	1.09M	3.67M	28M	62.71M	102.55M	118.08M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-1.2M	-5.33M	-41.67M	-83.63M	-126.14M	-144.07M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-3.46%	-6.82%	-1.01%	-0.51%	-0.14%
EBITDA+	-1.2M	-5.2M	-41.42M	-82.94M	-124.62M	-142.32M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-3.34%	-6.97%	-1%	-0.5%	-0.14%
D&A (Non-Cash Add-back)	0	132K	249K	691K	1.51M	1.75M
EBIT	-1.2M	-5.32M	-41.67M	-83.63M	-126.14M	-144.07M
Net Interest Income+	0	0	100K	1.81M	8.88M	5.64M
Interest Income	0	0	100K	1.81M	8.88M	5.64M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	-3K	3K	100K	1.81M	8.88M	5.64M
Pretax Income+	-1.2M	-5.32M	-41.57M	-81.83M	-117.25M	-138.43M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-1.2M	-5.32M	-41.57M	-81.83M	-117.25M	-138.43M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-3.44%	-6.81%	-0.97%	-0.43%	-0.18%
Net Income (Continuing)	-1.2M	-5.32M	-41.57M	-81.83M	-117.25M	-138.43M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.11	-0.50	-1.74	-2.80	-3.44	-3.83
EPS Growth %	-	-3.55%	-2.48%	-0.61%	-0.23%	-0.11%
EPS (Basic)	-0.11	-0.50	-1.74	-2.80	-3.44	-3.83
Diluted Shares Outstanding	10.71M	10.71M	23.86M	29.27M	34.11M	36.11M
Basic Shares Outstanding	10.71M	10.71M	23.86M	29.27M	34.11M	36.11M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	265K	62.22M	176.56M	117.82M	179.18M	68.33M
Cash & Short-Term Investments	239K	61.7M	173.52M	113.05M	176.87M	58.28M
Cash Only	239K	61.7M	145.74M	111.9M	176.87M	58.28M
Short-Term Investments	0	0	27.78M	1.15M	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	4.77M	2.31M	10.05M
Total Non-Current Assets+	0	303K	9.14M	11.49M	20.75M	11.61M
Property, Plant & Equipment	0	291K	5.69M	7.99M	14.87M	10.62M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	1.88M	0	0	0
Other Non-Current Assets	0	12K	1.58M	3.5M	5.87M	988K
Total Assets+	265K	62.53M	185.71M	129.31M	199.93M	79.94M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	234.95%	1.97%	-0.3%	0.55%	-0.6%
Total Current Liabilities+	286K	1.62M	4.64M	19.1M	22.86M	21.67M
Accounts Payable	271K	727K	1.33M	6.83M	6.85M	12.93M
Days Payables Outstanding	-	2.01K	-	-	-	-
Short-Term Debt	0	36K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	0	480K	636K	192K	203K
Current Ratio	0.93x	38.43x	38.08x	6.17x	7.84x	3.15x
Quick Ratio	0.93x	38.43x	38.08x	6.17x	7.84x	3.15x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	55.74M	2.29M	1.67M	7.83M	6.69M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	2.29M	1.67M	7.83M	6.69M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	55.74M	0	0	0	0
Total Liabilities	286K	57.36M	6.92M	20.77M	30.69M	28.36M
Total Debt+	0	259K	2.85M	2.29M	10.3M	8.77M
Net Debt	-239K	-61.44M	-142.89M	-109.61M	-166.57M	-49.51M
Debt / Equity	-	0.05x	0.02x	0.02x	0.06x	0.17x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	-21K	5.17M	178.78M	108.54M	169.24M	51.57M
Equity Growth %	-	247.14%	33.59%	-0.39%	0.56%	-0.7%
Book Value per Share	-0.00	0.48	7.49	3.71	4.96	1.43
Total Shareholders' Equity	-21K	5.17M	178.78M	108.54M	169.24M	51.57M
Common Stock	1K	1K	3K	3K	4K	4K
Retained Earnings	-2.85M	-8.18M	-49.74M	-131.57M	-248.82M	-387.25M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-10K	-1K	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.28M	-4.46M	-35.44M	-62.42M	-96.59M	-119.89M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-2.49%	-6.95%	-0.76%	-0.55%	-0.24%
Net Income	-1.2M	-5.32M	-41.57M	-81.83M	-117.25M	-138.43M
Depreciation & Amortization	0	132K	953K	691K	1.51M	0
Stock-Based Compensation	0	0	0	10.34M	14.13M	19.09M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	0	322K	6.75M	715K	2.69M	4.59M
Working Capital Changes	-81K	411K	-1.57M	7.67M	2.33M	-5.15M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	-98K	418K	640K	2.96M	2.56M	6.09M
Cash from Investing+	0	-51K	-33.35M	27.34M	-2.22M	-362K
Capital Expenditures	0	-51K	-3.17M	-1.03M	-3.37M	-362K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	1.44M	65.97M	153.19M	1.24M	163.8M	1.67M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	0	1.24M	2M	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-1.28M	-4.51M	-38.61M	-63.45M	-99.96M	-120.26M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-2.53%	-7.56%	-0.64%	-0.58%	-0.2%
FCF per Share	-0.12	-0.42	-1.62	-2.17	-2.93	-3.33
FCF Conversion (FCF/Net Income)	1.07x	0.84x	0.85x	0.76x	0.82x	0.87x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-206.84%	-45.19%	-56.96%	-84.42%	-125.38%
Return on Invested Capital (ROIC)	-	-	-	-360.26%	-11884.58%	-4566.89%
Debt / Equity	-	0.05x	0.02x	0.02x	0.06x	0.17x
FCF Conversion	1.07x	0.84x	0.85x	0.76x	0.82x	0.87x

Frequently Asked Questions

Growth & Financials

Biomea Fusion, Inc. (BMEA) grew revenue by 0.0% over the past year. Growth has been modest.

Biomea Fusion, Inc. (BMEA) reported a net loss of $95.7M for fiscal year 2024.

Dividend & Returns

Biomea Fusion, Inc. (BMEA) has a return on equity (ROE) of -125.4%. Negative ROE indicates the company is unprofitable.

Biomea Fusion, Inc. (BMEA) had negative free cash flow of $87.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener